Please Scroll Down to See Forums Below 
Male athletes with BF% around 20%+ are overweight and probably obese. 15% may be borderline overweight. These guys (and overweight/obese gals) should be concentrating on getting their BF% down before embarking on AAS cycles. After looking at blood testing and subjective results, I can conclude that HGH/cytomel cycles are the most effective for fat loss. Coupled with a high protein, low carb (<60g daily) and moderate clean fat diet, strength training and low-intensity cardio, you have the ideal fat loss regimen. Results are seen in a minimum of three month to six months. Both of these meds are readily available. The only disadvantage I have found is the cost of the HGH. But the good news is that once the fat is lost, low-dose AAS/antiestrogen and appropriate training and dieting will maintain the fat loss. Even though many users choose to stay "on" HGH indefinitely, it may not be necessary if using low-dose AAS for maintenance. Below is another recent study looking at HGH and fat loss. Through my studies, I have added cytomel to the stack with great success.
In addition, there is an Australian company that has isolated the HGH fragment responsible for lipolysis. They are in Phase II testing, and the results so far are successful. Interestingly, the pill isn't as effective for those will little need to lose fat as for those with 15%+ BF.
Low-dose recombinant human growth hormone as adjuvant therapy to lifestyle modifications in the management of obesity.
J Clin Endocrinol Metab 2004 Feb;89(2):695-701 (ISSN: 0021-972X)
Albert SG; Mooradian AD
Division of Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, St. Louis University School of Medicine, St. Louis, Missouri 63104, USA. [email protected].
Obese individuals are in a reduced GH/IGF-I state that may be maladaptive. Fifty-nine obese men and premenopausal menstruating women (body mass index, 36.9 +/- 5.0 kg/m(2)) were randomized to a double-blind, placebo-controlled trial of low dose recombinant human GH (rhGH). During the 6-month intervention, subjects self-administered daily rhGH or equivalent volume of placebo at 200 micro g (1.9 +/- 0.3 microg/kg for men, 2.0 +/- 0.3 microg/kg for women); after 1 month, the dose was increased to 400 microg (3.8 +/- 0.5 microg/kg) in men and 600 microg (6.0 +/- 0.8 microg/kg) in women. rhGH was then discontinued, and subjects were followed up after 3 months. Forty completed the intervention, and 39 completed the follow-up. Drop-out rates between rhGH vs. placebo groups were not different (chi(2) = 1.45; P = 0.228). One subject discontinued the drug due to an rhGH-related side effect. Body weight (BW) decreased with rhGH from 100.4 +/- 13.2 to 98.0 +/- 15.6 kg at 6 months (P = 0.04) and was sustained at 98.1 +/- 16.6 kg at 9 months (P = 0.02). BW loss was entirely due to loss of body fat (BF). Intention to treat analyses demonstrated changes from baseline between rhGH and placebo in BW (-2.16 +/- 4.48 vs. -0.04 +/- 2.67 kg; P = 0.03) and BF (-2.89 +/- 3.76 vs. -0.68 +/- 2.37 kg; P = 0.01). rhGH increased IGF-I from -0.72 to +0.10 SD (P = 0.0001). rhGH increased high-density lipoprotein cholesterol 19% from 1.11 +/- 0.34 to 1.32 +/- 0.28 mmol/liter (P < 0.001). Neither group had changes in fasting glucose, insulin sensitivity, or resting energy expenditure. In conclusion, in obesity, rhGH normalized IGF-I levels, induced loss of BW from BF, and improved lipid profile without untoward effects on insulin sensitivity.
In addition, there is an Australian company that has isolated the HGH fragment responsible for lipolysis. They are in Phase II testing, and the results so far are successful. Interestingly, the pill isn't as effective for those will little need to lose fat as for those with 15%+ BF.
Low-dose recombinant human growth hormone as adjuvant therapy to lifestyle modifications in the management of obesity.
J Clin Endocrinol Metab 2004 Feb;89(2):695-701 (ISSN: 0021-972X)
Albert SG; Mooradian AD
Division of Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, St. Louis University School of Medicine, St. Louis, Missouri 63104, USA. [email protected].
Obese individuals are in a reduced GH/IGF-I state that may be maladaptive. Fifty-nine obese men and premenopausal menstruating women (body mass index, 36.9 +/- 5.0 kg/m(2)) were randomized to a double-blind, placebo-controlled trial of low dose recombinant human GH (rhGH). During the 6-month intervention, subjects self-administered daily rhGH or equivalent volume of placebo at 200 micro g (1.9 +/- 0.3 microg/kg for men, 2.0 +/- 0.3 microg/kg for women); after 1 month, the dose was increased to 400 microg (3.8 +/- 0.5 microg/kg) in men and 600 microg (6.0 +/- 0.8 microg/kg) in women. rhGH was then discontinued, and subjects were followed up after 3 months. Forty completed the intervention, and 39 completed the follow-up. Drop-out rates between rhGH vs. placebo groups were not different (chi(2) = 1.45; P = 0.228). One subject discontinued the drug due to an rhGH-related side effect. Body weight (BW) decreased with rhGH from 100.4 +/- 13.2 to 98.0 +/- 15.6 kg at 6 months (P = 0.04) and was sustained at 98.1 +/- 16.6 kg at 9 months (P = 0.02). BW loss was entirely due to loss of body fat (BF). Intention to treat analyses demonstrated changes from baseline between rhGH and placebo in BW (-2.16 +/- 4.48 vs. -0.04 +/- 2.67 kg; P = 0.03) and BF (-2.89 +/- 3.76 vs. -0.68 +/- 2.37 kg; P = 0.01). rhGH increased IGF-I from -0.72 to +0.10 SD (P = 0.0001). rhGH increased high-density lipoprotein cholesterol 19% from 1.11 +/- 0.34 to 1.32 +/- 0.28 mmol/liter (P < 0.001). Neither group had changes in fasting glucose, insulin sensitivity, or resting energy expenditure. In conclusion, in obesity, rhGH normalized IGF-I levels, induced loss of BW from BF, and improved lipid profile without untoward effects on insulin sensitivity.
